Technology and Independent Agent Walletshare
Date: Thursday, October 27, 2011
Time: 12:00pm ET | 9:00am PT
With a prolonged soft market, what do agents expect from their top carriers?
Agents expect the most change over the next three years to come in the form of increasing their customer accessibility by expanding customer web transactions, expanding use of mobile technology and increasing more tech automation. But which technology-enabled capabilities are most critical in attracting and retaining the most productive agents?
This web seminar, based on recent proprietary survey data from Novarica, looks at what top agents expect from their top carriers, how they prefer to work with these carriers, and the role technology plays in driving relationships and the placement of business. It also delves into agents' future plans for increased production.
Karlyn Carnahan is a principal in Novarica's insurance practice, focused on claims, distribution, and IT planning. Karlyn is the primary researcher and author of the market leading reports on claims core systems, reinsurance, and Web 2.0 and is a widely recognized expert on these topics who has presented at numerous conferences and conducted numerous vendor selection projects for US insurers. She joined Novarica with an extensive career in the insurance industry including serving as Vice President of Marketing for Fireman's Fund commercial lines division, where she successfully launched multiple industry programs, expanded online customer self-service capabilities, and took a leading position in formulating IT strategy. She also served as Global Industry Manager for Sun Microsystems and Senior Vice President of Product Development for InsWeb. Earlier in her career, she held a variety of marketing and underwriting positions at NORCAL and Fireman's Fund. She holds an MBA from Stanford Business School and a Certified Property Casualty Underwriter (CPCU) designation.
Johnson & Johnson is warning users of its OneTouch Ping insulin pump that hackers could exploit a cybersecurity flaw to infuse additional doses of the diabetes drug without their knowledge.